Enfortumab Vedotin Shows Promise for Urothelial Carcinoma medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
A new type of drug that helps target chemotherapy directly to cancer cells significantly increases survival of patients with the most common form of bladder cancer, new research suggests.
The risk of death was 30% lower with the new drug than with chemotherapy, with an average survival of approximately 13 months for the new drug, according to the new study.
Urothelial cancer is the most common type of bladder cancer and accounts for around 90% of cases.
It can also be found in the renal pelvis (where urine collects inside the kidney), ureter (tube that connects the kidneys to the bladder) and urethra.
Share this article
Share this article
TOKYO and BOTHELL, Wash., Feb. 12, 2021 /PRNewswire/ Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., Astellas ) and Seagen Inc. (Nasdaq: SGEN) today announced primary results from the phase 3 EV-301 trial comparing PADCEV
® (enfortumab vedotin-ejfv) to chemotherapy in adult patients with locally advanced or metastatic urothelial cancer who were previously treated with platinum-based chemotherapy and a PD-1/L1 inhibitor. At the time of pre-specified interim analysis, patients who received PADCEV in the trial lived a median of 3.9 months longer than those who received chemotherapy. Median overall survival was 12.9 vs. 9.0 months, respectively (HR=0.70 [95 percent Confidence Interval (CI): 0.56-0.89], p=0.001). For patients in the PADCEV arm of the trial, maculopapular rash, fatigue and decreased neutrophil count were the most frequent Grade 3 or greater treatment-related adverse events (TRAEs) occurring in more tha
E-Mail
A new type of drug that helps target chemotherapy directly to cancer cells has been found to significantly increase survival of patients with the most common form of bladder cancer, according to results from a phase III clinical trial led in the UK by Queen Mary University of London and Barts Health NHS Trust.
The results are published in the
New England Journal of Medicine and were presented at the 2021 American Society of Clinical Oncology s Genitourinary Cancers Symposium.
Urothelial cancer is the most common type of bladder cancer (90 percent of cases) and can also be found in the renal pelvis (where urine collects inside the kidney), ureter (tube that connects the kidneys to the bladder) and urethra. Globally, approximately 549,000 new cases of bladder cancer and 200,000 deaths are reported annually.
email article
The antibody-drug conjugate (ADC) enfortumab vedotin significantly improved overall survival (OS) in patients with advanced, previously treated bladder cancer, a large randomized trial showed.
Median OS improved from about 9 months with standard chemotherapy to almost 13 months with enfortumab vedotin-ejfv (Padcev). Median progression-free survival also improved significantly with the ADC, from 3.71 to 5.55 months.
The incidence of treatment-related adverse events (TRAEs) was similar between treatment groups, including grade ≥3 TRAEs, reported Thomas Powles, MD, of Barts Cancer Center and Queen Mary University in London, during the virtual Genitourinary Cancers Symposium (GuCS). The results were published simultaneously in the Enfortumab vedotin is the first drug beyond chemotherapy and immune therapy to show a significant survival advantage in previously treated advanced urothelial cancer, said Powles. This is a big step in the right direction for patie